Our Mission: Improve the quality of health care. Our Vision: Better health care. Better choices. Better health. Points the way to health care that science says works. Studies how well health plans and doctors provide scientifically recommended care. Identifies organizations that are run in ways that make care better.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

news image

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More

Industrial Impact, Medical

CARIS LIFE SCIENCES AND FLARE THERAPEUTICS ANNOUNCE STRATEGIC PREFERRED PORTFOLIO PARTNERSHIP TO ADVANCE FLARE'S PRECISION ONCOLOGY PIPELINE

prnewswire | April 17, 2023

news image

Caris Life Sciences® the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced a multi-year strategic collaboration to accelerate precision medicine approaches across five of Flare's therapeutic programs into clinical trials through advanced molec...

Read More

AVENUEB CREATES A PATH TO SUCCESS FOR BIOLOGY STUDENTS

UC Davis | April 14, 2020

news image

The Genentech Foundation has donated $2.5 million to the University of California, Davis, College of Biological Sciences — the college’s largest single gift ever — to fund a program that will help biology students transferring from community college. Called AvenueB, the program will provide financial support and preparatory programs for students going to four-year university. According to the Campaign for College Opportunity, students transferring from community colleges to a U...

Read More

MOLECULIN ANNOUNCES DISCOVERY OF SIGNIFICANT IN VITRO ACTIVITY AGAINST SARS-COV-2

Moleculin | September 29, 2020

news image

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that its research team has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2. Independent laboratory testing of the new drug candidate, called "WP1096," has now repea...

Read More
news image

Cell and Gene Therapy

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More
news image

Industrial Impact, Medical

CARIS LIFE SCIENCES AND FLARE THERAPEUTICS ANNOUNCE STRATEGIC PREFERRED PORTFOLIO PARTNERSHIP TO ADVANCE FLARE'S PRECISION ONCOLOGY PIPELINE

prnewswire | April 17, 2023

Caris Life Sciences® the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced a multi-year strategic collaboration to accelerate precision medicine approaches across five of Flare's therapeutic programs into clinical trials through advanced molec...

Read More
news image

AVENUEB CREATES A PATH TO SUCCESS FOR BIOLOGY STUDENTS

UC Davis | April 14, 2020

The Genentech Foundation has donated $2.5 million to the University of California, Davis, College of Biological Sciences — the college’s largest single gift ever — to fund a program that will help biology students transferring from community college. Called AvenueB, the program will provide financial support and preparatory programs for students going to four-year university. According to the Campaign for College Opportunity, students transferring from community colleges to a U...

Read More
news image

MOLECULIN ANNOUNCES DISCOVERY OF SIGNIFICANT IN VITRO ACTIVITY AGAINST SARS-COV-2

Moleculin | September 29, 2020

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that its research team has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2. Independent laboratory testing of the new drug candidate, called "WP1096," has now repea...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us